<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007860.ref050">
 <label>50</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Larsen</surname>
   <given-names>RA</given-names>
  </name>, 
  <name>
   <surname>Pappas</surname>
   <given-names>PG</given-names>
  </name>, 
  <name>
   <surname>Perfect</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Aberg</surname>
   <given-names>JA</given-names>
  </name>, 
  <name>
   <surname>Casadevall</surname>
   <given-names>A</given-names>
  </name>, 
  <name>
   <surname>Cloud</surname>
   <given-names>GA</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis</article-title>. 
  <source>Antimicrob Agents Chemother</source>. 
  <year>2005</year>;
  <volume>49</volume>(
  <issue>3</issue>):
  <fpage>952</fpage>â€“
  <lpage>8</lpage>. 
  <pub-id pub-id-type="doi">10.1128/AAC.49.3.952-958.2005</pub-id>
  <?supplied-pmid 15728888?>
  <pub-id pub-id-type="pmid">15728888</pub-id>
 </mixed-citation>
</ref>
